Sanofi and clinical-stage biopharmaceutical company Inhibrx, Inc. announced a definitive agreement on 23 January 2024 under which Sanofi will acquire Inhibrx following the separation of its non-INBRX-101 assets into a newly established company, New Inhibrx. The transaction is valued at approximately $1.7 billion in equity value and will add INBRX-101, an investigational treatment for alpha-1 antitrypsin deficiency (AATD), to Sanofi’s rare disease development portfolio. INBRX-101 targets alpha-1 antitrypsin deficiency INBRX-101 is a human recombinant alpha-1 antitrypsin (AAT) protein being developed as an augmentation therapy for people with AATD, a rare inherited...